Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) Return on Sales (2020 - 2025)

Fennec Pharmaceuticals' Return on Sales history spans 6 years, with the latest figure at 0.15% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 34.0% year-over-year to 0.15%, compared with a TTM value of 0.06% through Dec 2025, down 7.0%, and an annual FY2025 reading of 0.22%, down 47.0% over the prior year.
  • Return on Sales for Q4 2025 was 0.15% at Fennec Pharmaceuticals, up from 0.05% in the prior quarter.
  • The five-year high for Return on Sales was 435.22% in Q2 2021, with the low at 94.54% in Q1 2021.
  • Average Return on Sales over 5 years is 33.44%, with a median of 0.13% recorded in 2025.
  • Biggest YoY gain for Return on Sales was 15653bps in 2022; the steepest drop was -34650bps in 2022.
  • Tracing FENC's Return on Sales over 5 years: stood at 76.64% in 2021, then crashed by -90bps to 7.54% in 2022, then tumbled by -104bps to 0.27% in 2023, then grew by 30bps to 0.19% in 2024, then surged by 182bps to 0.15% in 2025.
  • Per Business Quant, the three most recent readings for FENC's Return on Sales are 0.15% (Q4 2025), 0.05% (Q3 2025), and 0.33% (Q2 2025).